Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | KLK7 | P49862 | 2/20 | 0.53 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 2/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5800362 | 0.96 | MAPT (0.57) | MAPTKLK7KLK5CTSSFOLH1 | |
| SCHEMBL19345933 | 0.93 | SYK (0.54) | MAPTKLK7KLK5CTSSSYK | |
| SCHEMBL29458852 | 0.87 | SYK (0.58) | MAPTKLK5CTSSSYKCTSK | |
| SCHEMBL29458730 | 0.85 | MAPT (0.63) | MAPTKLK7KLK5ITGB3ITGA2B | |
| SCHEMBL16789691 | 0.83 | MAPT (0.63) | MAPTKLK7KLK5ITGB3ITGA2B | |
| SCHEMBL13430765 | 0.83 | MAPT (0.54) | MAPTKLK7KLK5ITGB3ITGA2B | |
| SCHEMBL19345774 | 0.83 | MAPT (0.60) | MAPTKLK7KLK5ITGB3ITGA2B | |
| SCHEMBL5707671 | 0.83 | MAPT (0.60) | MAPTKLK7KLK5ITGB3ITGA2B | |
| SCHEMBL5114952 | 0.83 | MAPT (0.60) | MAPTKLK7KLK5CTSSFOLH1 | |
| SCHEMBL10656550 | 0.82 | MAPT (0.62) | MAPTKLK7KLK5ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059231-A1 | Protease inhibitors | PROTINHI B.V. (NL) | 2025-02-20 | — | — | US | disclosed |
| WO-2024200819-A1 | PROTEASE INHIBITORS FOR CORONAVIRAL INFECTIONS | PROTINHI B.V. (NL) | 2024-10-03 | — | — | WO | disclosed |
| EP-4408454-A1 | PROTEASE INHIBITORS | Protinhi B.V. (NL) | 2024-08-07 | — | — | EP | disclosed |
| WO-2023052636-A1 | PROTEASE INHIBITORS | PROTINHI B.V. (NL) | 2023-04-06 | — | — | WO | disclosed |
| EP-3472130-B1 | ALIPHATIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2022-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059231-A1 | Protease inhibitors | PREP, DNPEP, TMPRSS15 | MAPT 1231/4885KLK7 1433/4885KLK5 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.